<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1699-714X</journal-id>
<journal-title><![CDATA[Revista de la OFIL ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. OFIL·ILAPHAR]]></abbrev-journal-title>
<issn>1699-714X</issn>
<publisher>
<publisher-name><![CDATA[Organización de Farmacéuticos Ibero-Latinoamericanos]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1699-714X2022000300008</article-id>
<article-id pub-id-type="doi">10.4321/s1699-714x2022000300008</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Polifarmacia en paciente VIH mayor de 50 años]]></article-title>
<article-title xml:lang="en"><![CDATA[Polypharmacy in HIV patient older than 50 years]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Enríquez-Olivar]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pasquau]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Clínico Universitario de Valladolid Servicio de Farmacia ]]></institution>
<addr-line><![CDATA[Valladolid ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Rey Juan Carlos Campus Esther ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2022</year>
</pub-date>
<volume>32</volume>
<numero>3</numero>
<fpage>255</fpage>
<lpage>261</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1699-714X2022000300008&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1699-714X2022000300008&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1699-714X2022000300008&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: Los pacientes con virus de la inmunodeficiencia humana (VIH) han aumentado su esperanza de vida, convirtiéndose así el VIH en una enfermedad crónica gracias al tratamiento antirretroviral (TAR), que aunque no sea capaz de erradicar el virus, mantiene la carga viral suprimida e incrementa el número de linfocitos-CD4. Consecuentemente, ha aumentado el número de comorbilidades en esta población, y con ello su polifarmacia.  Objetivo: Analizar la medicación TAR y no-TAR de pacientes VIH &#8805;50 años, determinando el grado de polifarmacia y las interacciones potenciales relevantes.  Material y métodos: Estudio retrospectivo, observacional, unicéntrico, analítico, transversal. Se incluyeron los pacientes VIH &#8805;50 años que acudieron al Servicio de Farmacia para recogida de medicación: 7-enero al 3-febrero, 2019. Se recogieron las variables: edad, sexo, estratificación según la Estrategia de Atención Farmacéutica al Paciente Crónico de Jimena® , TAR y medicación no-TAR.  Resultados: Se incluyeron un total de 114 pacientes &#8805;50 años, el 96,97% tenía medicación concomitante, destacando fármacos para el sistema cardiovascular y para el sistema nervioso central (SNC). Se identificaron 99 interacciones potenciales significativas TAR/no-TAR en 66 pacientes, ocurriendo principalmente con los fármacos para el SNC. Los TAR principalmente implicados fueron los inhibidores de la transcriptasa inversa no análogos de nucleósidos, inhibidores de la proteasa potenciados e inhibidores de la integrasa potenciados (INI/p).  Conclusiones: El médico prescriptor del TAR debe tener encuenta la polifarmacia de estos pacientes, intentar desprescribir medicación innecesaria en la medida de lo posible ybuscar alternativas con menor repercusión, como puede serel uso de INI en el contexto del TAR.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background: Human immunodeficiency virus (HIV) in patients have increased their life expectancy, making HIV a chronic illness, thanks to the antiretroviral treatment (ART), which, despite the fact it is not able to eradicate the HIV, it keeps the viral load supressed and increases the number of CD4 lymphocytes. Consequently, the number of comorbidities in this population has increased so, its polypharmacy as well.  Objective: To analyze the ART and nonART medication of HIV patients &#8805;50 years old, determining the degree of polypharmacy and relevant interactions.  Material and methods: Observational retrospective study, mono-site, analytical and transversal. HIV patients &#8805;50 years old who went to the Pharmacy Service for collecting medication from January 7th untill February 3rd, 2019. The following variables were selected: age, sex, stratification according to the Strategy of Pharmaceutical Care to the Patient Chronic of Jimena®, ART and non-ART medication.  Results: A total of 114 patients &#8805;50 years old were included, 96.97% had concomitant medication, highlighting drugsfor the cardiovascular system and for the central nervous system. 99 significant interactions ART/non-ART were identified in 66 patients, occurring mainly with drugs for the central nervous system. The ARTs mainly involved were the nonnucleoside reverse transcriptase inhibitors, boosted protease inhibitors and boosted integrase inhibitors (INI).Conclusions: Prescribe physicians of ARTs must take into account to the polypharmacy of the patients, try to deprescribe unnecessary medication as much as possible and find alternatives with less repercussion, such as the use of Inhibitors of the Integrase, in the context of ART]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Polifarmacia]]></kwd>
<kwd lng="es"><![CDATA[desprescripción]]></kwd>
<kwd lng="es"><![CDATA[infección VIH]]></kwd>
<kwd lng="en"><![CDATA[Polipharmacy]]></kwd>
<kwd lng="en"><![CDATA[deprescription]]></kwd>
<kwd lng="en"><![CDATA[HIV infection]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bernal]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Brañas]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Folguera]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gimeno]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lázaro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Olalla]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Robustillo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Rubio]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tuset]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Desprescripción farmacológica de la terapia no antirretroviral en pacientes con infección por VIH]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="book">
<source><![CDATA[Vivir con el VIH: retos en la gestión del VIH en España]]></source>
<year>2017</year>
<publisher-name><![CDATA[The Economist Intelligence Unit Limited]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Greene]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Steinman]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[McNicholl]]></surname>
<given-names><![CDATA[IR]]></given-names>
</name>
<name>
<surname><![CDATA[Valcour]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Polypharmacy, Drug-Drug Interactions, and Potentially Inappropriate Medications in Older HIV-Infected]]></article-title>
<source><![CDATA[]]></source>
<year>2014</year>
<volume>62</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>447-53</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="">
<source><![CDATA[Cohorte Española VACH]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="">
<source><![CDATA[Base de datos Liverpool]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morillo-Verdugo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Robustillo-Corté]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Abdel-Kader Martín]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez de Sotomayor Paz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lozano de León Naranjo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Victoria Almeida-González]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of Polypharmacy and Association to Pharmacotherapy Complexity in Older HIV-Positive Patients. The Sevihlla Study]]></article-title>
<source><![CDATA[IJOAR]]></source>
<year>2019</year>
<volume>2</volume>
<numero>35</numero>
<issue>35</issue>
<page-range>2637-3742</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guaraldi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Menozzi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zona]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of polypharmacy on antiretroviral prescription in people living with HIV]]></article-title>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>2017</year>
<volume>72</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>511-4</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gimeno-Gracia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Crusells-Canales]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Javier Armesto-Gomez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[RabanaqueHernandez]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of concomitant medications in older HIV+ patients and comparison with general population]]></article-title>
<source><![CDATA[HIV clinical trials]]></source>
<year>2015</year>
<volume>16</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>117-24</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rockwood]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Mitnitski]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frailty defined by deficit accumulation and geriatric medicine defined by frailty]]></article-title>
<source><![CDATA[Clinics in geriatric medicine]]></source>
<year>2011</year>
<volume>27</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>17-26</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
